These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 19038000)

  • 1. Using gene expression profiling to identify a prognostic molecular spectrum in gliomas.
    Shirahata M; Oba S; Iwao-Koizumi K; Saito S; Ueno N; Oda M; Hashimoto N; Ishii S; Takahashi JA; Kato K
    Cancer Sci; 2009 Jan; 100(1):165-72. PubMed ID: 19038000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification.
    Nutt CL; Mani DR; Betensky RA; Tamayo P; Cairncross JG; Ladd C; Pohl U; Hartmann C; McLaughlin ME; Batchelor TT; Black PM; von Deimling A; Pomeroy SL; Golub TR; Louis DN
    Cancer Res; 2003 Apr; 63(7):1602-7. PubMed ID: 12670911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
    Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
    Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TERT promoter mutations contribute to subset prognostication of lower-grade gliomas.
    Chan AK; Yao Y; Zhang Z; Chung NY; Liu JS; Li KK; Shi Z; Chan DT; Poon WS; Zhou L; Ng HK
    Mod Pathol; 2015 Feb; 28(2):177-86. PubMed ID: 25081751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
    Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
    Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription-polymerase chain reaction.
    van den Boom J; Wolter M; Kuick R; Misek DE; Youkilis AS; Wechsler DS; Sommer C; Reifenberger G; Hanash SM
    Am J Pathol; 2003 Sep; 163(3):1033-43. PubMed ID: 12937144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups.
    Weller M; Weber RG; Willscher E; Riehmer V; Hentschel B; Kreuz M; Felsberg J; Beyer U; Löffler-Wirth H; Kaulich K; Steinbach JP; Hartmann C; Gramatzki D; Schramm J; Westphal M; Schackert G; Simon M; Martens T; Boström J; Hagel C; Sabel M; Krex D; Tonn JC; Wick W; Noell S; Schlegel U; Radlwimmer B; Pietsch T; Loeffler M; von Deimling A; Binder H; Reifenberger G
    Acta Neuropathol; 2015 May; 129(5):679-93. PubMed ID: 25783747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
    Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
    EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma.
    Gorovets D; Kannan K; Shen R; Kastenhuber ER; Islamdoust N; Campos C; Pentsova E; Heguy A; Jhanwar SC; Mellinghoff IK; Chan TA; Huse JT
    Clin Cancer Res; 2012 May; 18(9):2490-501. PubMed ID: 22415316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas.
    Cooper LA; Gutman DA; Long Q; Johnson BA; Cholleti SR; Kurc T; Saltz JH; Brat DJ; Moreno CS
    PLoS One; 2010 Sep; 5(9):e12548. PubMed ID: 20838435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients.
    Mukasa A; Takayanagi S; Saito K; Shibahara J; Tabei Y; Furuya K; Ide T; Narita Y; Nishikawa R; Ueki K; Saito N
    Cancer Sci; 2012 Mar; 103(3):587-92. PubMed ID: 22136423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular classification of human gliomas using matrix-based comparative genomic hybridization.
    Roerig P; Nessling M; Radlwimmer B; Joos S; Wrobel G; Schwaenen C; Reifenberger G; Lichter P
    Int J Cancer; 2005 Oct; 117(1):95-103. PubMed ID: 15880582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular classification of human diffuse gliomas by multidimensional scaling analysis of gene expression profiles parallels morphology-based classification, correlates with survival, and reveals clinically-relevant novel glioma subsets.
    Fuller GN; Hess KR; Rhee CH; Yung WK; Sawaya RA; Bruner JM; Zhang W
    Brain Pathol; 2002 Jan; 12(1):108-16. PubMed ID: 11771519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. cMYC expression in infiltrating gliomas: associations with IDH1 mutations, clinicopathologic features and outcome.
    Odia Y; Orr BA; Bell WR; Eberhart CG; Rodriguez FJ
    J Neurooncol; 2013 Nov; 115(2):249-59. PubMed ID: 23934175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Relevance of Histomolecular Classification of Diffuse Adult High-Grade Gliomas with Necrosis.
    Figarella-Branger D; Mokhtari K; Colin C; Uro-Coste E; Jouvet A; Dehais C; Carpentier C; Villa C; Maurage CA; Eimer S; Polivka M; Vignaud JM; Laquerriere A; Sevestre H; Lechapt-Zalcman E; Quintin-Roué I; Aubriot-Lorton MH; Diebold MD; Viennet G; Adam C; Loussouarn D; Michalak S; Rigau V; Heitzmann A; Vandenbos F; Forest F; Chiforeanu D; Tortel MC; Labrousse F; Chenard MP; Nguyen AT; Varlet P; Kemeny JL; Levillain PM; Cazals-Hatem D; Richard P; Delattre JY;
    Brain Pathol; 2015 Jul; 25(4):418-28. PubMed ID: 25407774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clonal analysis of gliomas.
    Kattar MM; Kupsky WJ; Shimoyama RK; Vo TD; Olson MW; Bargar GR; Sarkar FH
    Hum Pathol; 1997 Oct; 28(10):1166-79. PubMed ID: 9343324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression analyses of grade II gliomas and identification of rPTPbeta/zeta as a candidate oligodendroglioma marker.
    Hägerstrand D; Smits A; Eriksson A; Sigurdardottir S; Olofsson T; Hartman M; Nistér M; Kalimo H; Ostman A
    Neuro Oncol; 2008 Feb; 10(1):2-9. PubMed ID: 18003890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High miR-196a and low miR-367 cooperatively correlate with unfavorable prognosis of high-grade glioma.
    Guan Y; Chen L; Bao Y; Qiu B; Pang C; Cui R; Wang Y
    Int J Clin Exp Pathol; 2015; 8(6):6576-88. PubMed ID: 26261539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
    BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of the 2016 WHO classification in Japanese patients with gliomas.
    Iuchi T; Sugiyama T; Ohira M; Kageyama H; Yokoi S; Sakaida T; Hasegawa Y; Setoguchi T; Itami M
    Brain Tumor Pathol; 2018 Apr; 35(2):71-80. PubMed ID: 29470683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.